Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (6): 947-949. doi: 10.19723/j.issn.1671-167X.2024.06.001
CLC Number:
1 |
Barilaro G , Esteves A , Della-Rocca C , et al. Predictive value of the adjusted Global Anti-Phospholipid Syndrome Score on clinical recurrence in APS patients: A longitudinal study[J]. Rheumatology (Oxford), 2023, 62 (4): 1576- 1585.
doi: 10.1093/rheumatology/keac485 |
2 |
Cervera R , Serrano R , Pons-Estel GJ , et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients[J]. Ann Rheum Dis, 2015, 74 (6): 1011- 1018.
doi: 10.1136/annrheumdis-2013-204838 |
3 |
Sevim E , Zisa D , Andrade D , et al. Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository[J]. Arthritis Care Res (Hoboken), 2022, 74 (2): 324- 335.
doi: 10.1002/acr.24468 |
4 |
Cervera R , Rodríguez-Pintó I , Espinosa G . The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review[J]. J Autoimmun, 2018, 92, 1- 11.
doi: 10.1016/j.jaut.2018.05.007 |
5 |
Tektonidou MG , Andreoli L , Limper M , et al. EULAR recommendations for the management of antiphospholipid syndrome in adults[J]. Ann Rheum Dis, 2019, 78 (10): 1296- 1304.
doi: 10.1136/annrheumdis-2019-215213 |
6 |
Crowther MA , Ginsberg JS , Julian J , et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome[J]. N Engl J Med, 2003, 349 (12): 1133- 1138.
doi: 10.1056/NEJMoa035241 |
7 |
Finazzi G , Marchioli R , Brancaccio V , et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)[J]. J Thromb Haemost, 2005, 3 (5): 848- 853.
doi: 10.1111/j.1538-7836.2005.01340.x |
8 |
Pengo V , Denas G , Zoppellaro G , et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome[J]. Blood, 2018, 132 (13): 1365- 1371.
doi: 10.1182/blood-2018-04-848333 |
9 |
Ordi-Ros J , Sáez-Comet L , Pérez-Conesa M , et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: A randomized noninferiority trial[J]. Ann Intern Med, 2019, 171 (10): 685- 694.
doi: 10.7326/M19-0291 |
10 |
Pengo V , Testa S , Martinelli I , et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant[J]. Thromb Res, 2015, 135 (1): 46- 49.
doi: 10.1016/j.thromres.2014.10.013 |
11 |
Yelnik CM , Urbanski G , Drumez E , et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity[J]. Lupus, 2017, 26 (2): 163- 169.
doi: 10.1177/0961203316657433 |
12 |
Mustonen P , Lehtonen KV , Javela K , et al. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: A nationwide prospective study[J]. Lupus, 2014, 23 (14): 1468- 1476.
doi: 10.1177/0961203314545410 |
13 |
Ruffatti A , Del-Ross T , Ciprian M , et al. Risk factors for a first thrombotic event in antiphospholipid antibody carriers: A prospective multicentre follow-up study[J]. Ann Rheum Dis, 2011, 70 (6): 1083- 1086.
doi: 10.1136/ard.2010.142042 |
14 |
Zuo Y , Barbhaiya M , Erkan D . Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: Where do we stand in 2018[J]. Curr Rheumatol Rep, 2018, 20 (11): 66.
doi: 10.1007/s11926-018-0775-8 |
15 |
Erkan D , Harrison MJ , Levy R , et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals[J]. Arthritis Rheum, 2007, 56 (7): 2382- 2391.
doi: 10.1002/art.22663 |
16 |
Arnaud L , Mathian A , Ruffatti A , et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: An international and collaborative meta-analysis[J]. Autoimmun Rev, 2014, 13 (3): 281- 291.
doi: 10.1016/j.autrev.2013.10.014 |
17 |
Arnaud L , Mathian A , Devilliers H , et al. Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies[J]. Autoimmun Rev, 2015, 14 (3): 192- 200.
doi: 10.1016/j.autrev.2014.10.019 |
18 |
Watanabe T , Oku K , Amengual O , et al. Effects of statins on thrombosis development in patients with systemic lupus erythematosus and antiphospholipid antibodies[J]. Lupus, 2018, 27 (2): 225- 234.
doi: 10.1177/0961203317716787 |
19 |
Erkan D , Willis R , Murthy VL , et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients[J]. Ann Rheum Dis, 2014, 73 (6): 1176- 1180.
doi: 10.1136/annrheumdis-2013-203622 |
20 |
Cohen H , Cuadrado MJ , Erkan D , et al. 16th International Congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends[J]. Lupus, 2020, 29 (12): 1571- 1593.
doi: 10.1177/0961203320950461 |
21 |
Erkan D , Unlu O , Sciascia S , et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease[J]. Lupus, 2018, 27 (3): 399- 406.
doi: 10.1177/0961203317724219 |
22 |
Cohen H , Sayar Z , Efthymiou M , et al. Management of anticoagulant-refractory thrombotic antiphospholipid syndrome[J]. Lancet Haematol, 2020, 7 (8): e613- e623.
doi: 10.1016/S2352-3026(20)30116-2 |
23 |
Mormile I , Granata F , Punziano A , et al. Immunosuppressive treatment in antiphospholipid syndrome: Is it worth it?[J]. Biomedicines, 2021, 9 (2): 132.
doi: 10.3390/biomedicines9020132 |
24 |
Rodríguez-Pintó I , Espinosa G , Erkan D , et al. The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients[J]. Rheumatology (Oxford), 2018, 57 (7): 1264- 1270.
doi: 10.1093/rheumatology/key082 |
25 |
Berman H , Rodríguez-Pintó I , Cervera R , et al. Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab[J]. Autoimmun Rev, 2013, 12 (11): 1085- 1090.
doi: 10.1016/j.autrev.2013.05.004 |
26 |
Yelnik CM , Miranda S , Mékinian A , et al. Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab[J]. Blood, 2020, 136 (21): 2473- 2477.
doi: 10.1182/blood.2020007499 |
27 | Bala MM , Celinska-Lowenhoff M , Szot W , et al. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome[J]. Cochrane Database Syst Rev, 2020, 10 (10): CD012169. |
28 |
Yelnik CM , Erton ZB , Drumez E , et al. Thrombosis recurrence and major bleeding in non-anticoagulated thrombotic antiphospholipid syndrome patients: Prospective study from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) clinical database and repository ("Registry")[J]. Semin Arthritis Rheum, 2024, 65, 152347.
doi: 10.1016/j.semarthrit.2023.152347 |
29 |
Medina G , Briones-García E , Cruz-Domínguez MP , et al. Antiphospholipid antibodies disappearance in primary antiphospholipid syndrome: Thrombosis recurrence[J]. Autoimmun Rev, 2017, 16 (4): 352- 354.
doi: 10.1016/j.autrev.2017.02.004 |
30 |
Radin M , Schreiber K , Sciascia S , et al. Prevalence of antiphospholipid antibodies negativisation in patients with antiphospholipid syndrome: A long-term follow-up multicentre study[J]. Thromb Haemost, 2019, 119 (12): 1920- 1926.
doi: 10.1055/s-0039-1696687 |
31 |
Zen M , Loredo-Martinez M , Benvenuti F , et al. Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion[J]. Rheumatology (Oxford), 2021, 60 (3): 1313- 1320.
doi: 10.1093/rheumatology/keaa463 |
32 |
Cuadrado MJ , Tincani A , Enriquez-Merayo E , et al. Can anticoagulation be withdrawn in APS patients after aPL negativization[J]. Autoimmun Rev, 2024, 23 (1): 103427.
doi: 10.1016/j.autrev.2023.103427 |
33 |
Ballul T , Mageau A , Roland Nicaise P , et al. Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome[J]. Thromb Res, 2023, 224, 1- 3.
doi: 10.1016/j.thromres.2023.02.005 |
34 |
Perez-Sanchez C , Barbarroja N , Messineo S , et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus[J]. Ann Rheum Dis, 2015, 74 (7): 1441- 1449.
doi: 10.1136/annrheumdis-2013-204600 |
[1] | Yijun HAN, Xiaoli CHEN, Changhong LI, Jinxia ZHAO. Application status of methotrexate in patients with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 994-1000. |
[2] | Jiayu ZHAI, Jinxia ZHAO, Zhuo AN, Rui LIU. Assessment of residual symptoms in patients with axial spondyloarthritis with low disease activity and analysis of its related factors [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 987-993. |
[3] | Yujing ZHU, Lei WANG, Chengyin LYU, Wenfeng TAN, Miaojia ZHANG. Analysis of clinical features of ruccrent interstitial lung disease in patients with anti-EJ positive antisynthetase syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 980-986. |
[4] | Liang ZHAO, Chenglong SHI, Ke MA, Jing ZHAO, Xiao WANG, Xiaoyan XING, Wanxing MO, Yirui LIAN, Chao GAO, Yuhui LI. Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 972-979. |
[5] | Meijuan LONG, Yidan WANG, Shiya WU, Zihao LI, Yanting LI, Yang LI, Juan JIAO. Effects of overweight and obesity on symptoms, overall condition and quality of life in patients with fibromyalgia syndrome [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1001-1008. |
[6] | Peiwen JIA, Ying YANG, Yaowei ZOU, Zhiming OUYANG, Jianzi LIN, Jianda MA, Kuimin YANG, Lie DAI. Clinical characteristics of overlapping syndromes of low muscle mass in patients with rheumatoid arthritis and their impact on physical function [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1009-1016. |
[7] | Hongyan WANG, Xinming LI, Kechi FANG, Huaqun ZHU, Rulin JIA, Jing WANG. Analysis of characteristics related to the disease activity of systemic lupus erythematosus and construction of an evaluation model [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1017-1022. |
[8] | Dandan CHEN, Yun LI, Qingyi LU, Xiaohong XIANG, Feng SUN, Yingni LI, Jing ZHAO, Hongyan WANG, Chun LI. Ovarian function in patients of childbearing age with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1023-1028. |
[9] | Li WANG, Chao GAO, Huanhuan REN, Yanping SHEN, Xiaowei HUANG, Hong YAO, Dandan HAN. Current status and influential factors of self-management ability in patients with systemic lupus erythematosus [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1029-1035. |
[10] | Yukai LI, Hongyan WANG, Liang LUO, Yun LI, Chun LI. Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1036-1040. |
[11] | Wei PAN, Yun LI, Junjia LUO, Chun LI, Hua YE, Xue LI, Yuan JIA. COVID-19 vaccines efficacy and infection features in patients with systemic sclerosis: A single-center cohort study [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1041-1046. |
[12] | Yan DING, Chaoran LI, Wensheng HUANG, Linzhong ZHU, Lifang WANG, Doudou MA, Juan ZHANG, Lianjie SHI. IgA vasculitis with necrosis of the small intestine secondary to monoclonal gammopathy of renal significance: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1101-1105. |
[13] | Doudou MA, Zhemin LU, Qian GUO, Sha ZHU, Jin GU, Yan DING, Lianjie SHI. Successful treatment of rheumatoid arthritis complicated with myasthenia gravis with low-dose rituximab: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1110-1114. |
[14] | Jing CHAI, Yue WANG, Rong MU, Jinxia ZHAO. Systemic lupus erythematosus involving the fornix column leading to hyponatremia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1115-1118. |
[15] | Mingxia WANG, Ling DING, Min WANG, Chanjuan ZOU, Siyu YAN, Yingwen LIANG, Weijia WANG, Shanzhi HE. Safe pregnancy and delivery in a female patient with systemic lupus erythematosus after discontinuation of dual-target chimeric antigen receptor T cells therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1119-1125. |
|